中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
3期
307-308
,共2页
高爱民%安智%程延娜%雒华%王妍妮
高愛民%安智%程延娜%雒華%王妍妮
고애민%안지%정연나%락화%왕연니
肾脏病学%肾小球肾炎%肾小球肾炎,IgA%肾脏用药%肾康注射液
腎髒病學%腎小毬腎炎%腎小毬腎炎,IgA%腎髒用藥%腎康註射液
신장병학%신소구신염%신소구신염,IgA%신장용약%신강주사액
Nephrology%Glomerulonephritis%Glomerulonephritis,IgA%Renal agents%Shenkang injection
目的 观察肾康注射液治疗早期慢性肾脏病的临床疗效和安全性.方法 66例慢性肾脏病2期患者(慢性肾小球肾炎37例,IgA肾病Ⅱ～Ⅲ级15例,过敏性紫癜肾炎14例)在血压控制平稳的基础上静脉滴注肾康注射液,30 d为1个疗程,连续治疗4个疗程.观察BUN、血肌酐(Scr)、血清胱抑素C(CysC)、肾小球滤过率(GFR)等变化,并记录不良反应.结果 治疗总有效率为80.3％(53/66).第2、4个疗程末BUN指标较治疗前下降[(6.68±0.76)、(6.12±0.88) mmol/L比(7.23±0.44) mmoL/L,P＜0.05,P＜0.01]；第1、2、4个疗程末Cys C比治疗前均下降[(1.11±0.12)、(0.94±0.11)、(0.80±0.12) mg/L比( 1.34±0.14) mg/L,均P＜0.01]；第4个疗程末24h尿蛋白定量和纤维蛋白原较治疗前均下降,差异均有统计学意义(均P＜0.05).第2、4个疗程GFR比治疗前上升[(77.4±9.2)、(80.6±8.8)ml/min比(70.9±9.3) ml/min,均P＜0.05].治疗过程中无明显不良反应发生.结论 肾康注射液可有效减缓部分早期慢性肾脏病患者的肾脏病进展,并有较好的安全性.
目的 觀察腎康註射液治療早期慢性腎髒病的臨床療效和安全性.方法 66例慢性腎髒病2期患者(慢性腎小毬腎炎37例,IgA腎病Ⅱ～Ⅲ級15例,過敏性紫癜腎炎14例)在血壓控製平穩的基礎上靜脈滴註腎康註射液,30 d為1箇療程,連續治療4箇療程.觀察BUN、血肌酐(Scr)、血清胱抑素C(CysC)、腎小毬濾過率(GFR)等變化,併記錄不良反應.結果 治療總有效率為80.3％(53/66).第2、4箇療程末BUN指標較治療前下降[(6.68±0.76)、(6.12±0.88) mmol/L比(7.23±0.44) mmoL/L,P＜0.05,P＜0.01]；第1、2、4箇療程末Cys C比治療前均下降[(1.11±0.12)、(0.94±0.11)、(0.80±0.12) mg/L比( 1.34±0.14) mg/L,均P＜0.01]；第4箇療程末24h尿蛋白定量和纖維蛋白原較治療前均下降,差異均有統計學意義(均P＜0.05).第2、4箇療程GFR比治療前上升[(77.4±9.2)、(80.6±8.8)ml/min比(70.9±9.3) ml/min,均P＜0.05].治療過程中無明顯不良反應髮生.結論 腎康註射液可有效減緩部分早期慢性腎髒病患者的腎髒病進展,併有較好的安全性.
목적 관찰신강주사액치료조기만성신장병적림상료효화안전성.방법 66례만성신장병2기환자(만성신소구신염37례,IgA신병Ⅱ～Ⅲ급15례,과민성자전신염14례)재혈압공제평은적기출상정맥적주신강주사액,30 d위1개료정,련속치료4개료정.관찰BUN、혈기항(Scr)、혈청광억소C(CysC)、신소구려과솔(GFR)등변화,병기록불량반응.결과 치료총유효솔위80.3％(53/66).제2、4개료정말BUN지표교치료전하강[(6.68±0.76)、(6.12±0.88) mmol/L비(7.23±0.44) mmoL/L,P＜0.05,P＜0.01]；제1、2、4개료정말Cys C비치료전균하강[(1.11±0.12)、(0.94±0.11)、(0.80±0.12) mg/L비( 1.34±0.14) mg/L,균P＜0.01]；제4개료정말24h뇨단백정량화섬유단백원교치료전균하강,차이균유통계학의의(균P＜0.05).제2、4개료정GFR비치료전상승[(77.4±9.2)、(80.6±8.8)ml/min비(70.9±9.3) ml/min,균P＜0.05].치료과정중무명현불량반응발생.결론 신강주사액가유효감완부분조기만성신장병환자적신장병진전,병유교호적안전성.
Objective To observe the clinical efficacy and safety of shenkang injection in treatment of partly chronic kidney disease ( chronic kidney disease,CKD 2 period) in early stage.Methods On the basis of stable blood pressure control,66 patients with CKD 2 disease were given shenkang injection for 4 courses with 30 days as a course.Clinical indices such as urea nitrogen( BUN),serum creatinine(Scr),cystatin-C (CysC),glomerular filtration rate( GFR),hemoglobin( Hb),urine protein quantity per 24 hours and fibrinogen were tested; clinical efficacy and adverse reactions were recorded.Results After treatment,the clinical efficiency was 80.3％.BUN,CysC,urine protein quantity per 24 hours and fibrinogen decreased greatly [(6.68 ±0.76) mmol/L vs (7.23 ±0.44) mmol/L,P ＜ 0.05 ; ( 6.12 ± 0.88 ) mmol/L vs ( 7.23 ± 0.44 ) mmol/L,P ＜ 0.01] ; there were significant differences of CysC of the 1st,2nd and 4th courses of treatment before and after treatment [( 1.11 ± 0.12 ),(0.94 ±0.11 ),(0.80 ±0.12)mg/L vs (1.34 ± 0.14)mg/L respectively,P ＜ 0.01]; there were significant differences of urine protein quantity per 24 hours and fibrinogen of the 4th courses of treatment before and after treatment,[P ＜ 0.05 and P ＜0.01,respectively].After treatment,GFR and Hb increased greatly.There were significant differences of GFR and Hb of the 2nd and 4th courses of treatment,compared with those of before-treatment[GFR:(77.4 ±9.2),(80.6 ± 8.8 ) ml/min vs ( 70.9 ± 9.3 ) ml/min,P ＜ 0.05.The adverse reactions showed no significant differences.Conclusion Shenkang injection is safe and effective in relieving CKD progress on CKD in the early stage.
